Contact

Terms of Use

The term ‘OGD2 Pharma’ or ‘us’ or ‘we’ refers to the owner of the website. The term ‘you’ refers to the user or viewer of our website.

The use of this website is subject to the following terms of use:

  • The content of the pages of this website is for your general information and use only. It is subject to change without notice.
  • Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.
  • Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.
  • This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.
  • All trademarks reproduced in this website, which are not the property of, or licensed to the operator, are acknowledged on the website.
  • Unauthorised use of this website may give to a claim for damages and/or be a criminal offence.
  • From time to time this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).
  • You may not create a link to this website from another website or document without OGD2 Pharma’s prior written consent. 
  • Your use of this website and any dispute arising out of such use of the website is subject to the laws of Switzerland.

Thank you for your message. We have received your request and appreciate your interest in our services. Our team will review it and get back to you as soon as possible with a response.

We look forward to speaking with you soon.

Margaret (Meg) Macy

Director, Experimental Therapeutics Program, Children's Hospital Colorado

Dr. Macy directs the Experimental Therapeutics Program at Children’s Hospital Colorado, the only early-phase paediatric oncology trial centre in the Rocky Mountain Region. She serves as institutional principal investigator for both the Pediatric Early Phase Clinical Trials Network (PEP-CTN) and the New Agents in Neuroblastoma Therapy (NANT) consortium. Her research focuses on relapsed/refractory neuroblastoma, with leadership roles across multiple COG and NANT trials including ANBL1821, ANBL2421, and a novel international biomarker platform study. She also serves as Medical Director for the Colorado Child Health Research Institute, with a particular focus on precision medicine and high-risk therapeutics.

Steve Dubois

Professor of Paediatrics, Harvard Medical School

Dr. Dubois is Director of Experimental Therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, leading programmes to advance targeted therapies for paediatric cancers. He holds a Master of Science in Epidemiology from Harvard School of Public Health and trained in paediatric oncology at Dana-Farber/Boston Children’s Hospital. His translational research focuses on neuroblastoma and Ewing sarcoma, spanning Phase I–III clinical trials and biomarker discovery. He has served on the Children’s Oncology Group Neuroblastoma Steering Committee, ASCO Scientific Program Committee, and the FDA Paediatric Oncology Drugs Advisory Committee.

Andy Pearson

Professor of Paediatric Oncology, ICR & Royal Marsden Hospital (Retired)

Professor Pearson is a globally recognised authority in neuroblastoma with 50 years of clinical and drug development experience. He held the Cancer Research UK Chair of Paediatric Oncology at the Institute of Cancer Research and served as Divisional Medical Director at the Royal Marsden Hospital. He chaired the UKCCSG Neuroblastoma Group, the European Neuroblastoma Group, and co-founded the International Neuroblastoma Risk Group. He chairs the ACCELERATE-EMA-FDA Paediatric Strategy Forum and LifeArc’s Childhood Cancer Translational Challenge. With over 430 publications and a Lifetime Achievement Award from Advances in Neuroblastoma Research, he is among the field’s most distinguished leaders.

Alice Yu

Distinguished Chair Professor, Chang Gung Memorial Hospital & Chang Gung University, Taiwan

A pioneer in cancer immunotherapy and Academician of Academia Sinica, Dr. Yu led dinutuximab from preclinical development through FDA approval in 2015, which established anti-GD2 therapy as standard of care for high-risk neuroblastoma. She is Professor Emeritus of Pediatrics at UC San Diego and Distinguished Chair Professor at Chang Gung Memorial Hospital. A long-standing member of the COG Neuroblastoma Steering Committee, she holds multiple distinguished awards including the 2025 Lifetime Achievement Award from Advances in Neuroblastoma Research and the 2020 ASCO Pediatric Oncology Award.

Brigitte Assouline

VP, Preclinical Development and IP

Expert in integrating preclinical science, regulatory strategy, and intellectual property to support clinical translation and asset differentiation.

Linkedin

Marco Alessandrini

COO & Business Development

Biotech executive with 15+ years of experience across advanced therapies, focused on strategy, operations, and strategic partnerships.

Linkedin

Jean-Marc Le Doussal

Founder & President

Immunologist, entrepreneur, and investor with a long track record of translating immunology into medicines and building science-driven biotech companies.

Linkedin